Santen Pharmaceutical Co., Ltd.: Dry Eye Syndromes trials

The registry lists 15 Dry Eye Syndromes studies with Santen Pharmaceutical Co., Ltd. as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 6Phase 3 3Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)CompletedNCT04144413Phase 3Results posted
• Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe KeratitisCompletedNCT03237936Phase 4Results posted
• Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01240382Phase 3Results posted
• Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01189032Phase 2Results posted
• 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisCompletedNCT04701086Not applicable
• 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisActive, not recruitingNCT04685109Not applicable
• Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye DiseaseCompletedNCT03216096Phase 1
• A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren SyndromeCompletedNCT02011776
• A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedNCT01468168Phase 2
• Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye DiseaseCompletedNCT01239069Phase 2
• Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedNCT01118754Phase 1/2
• Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01101984Not applicable
• A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) ModelCompletedNCT00814944Phase 2
• Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye SyndromeCompletedNCT00814515Phase 3
• NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry EyeCompletedNCT00739349Phase 2